WVE Wave Life Sciences Ltd.

25.46
-0.12  -0%
Previous Close 25.58
Open 25.37
Price To Book 11.84
Market Cap 870531019
Shares 34,192,106
Volume 225,504
Short Ratio
Av. Daily Volume 503,322

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2a top line data due by YE 2019.
WVE-120101
Huntington’s disease
Phase 1b/2a top line data due by YE 2019.
WVE-120102
Huntington’s disease
Phase 1 interim efficacy data from open-label trial due 2H 2019. Phase 2/3 trial to be initiated July 2019.
Suvodirsen (WVE-210201)
Duchenne muscular dystrophy - Exon 51

Latest News

  1. Wave Life Sciences Plunges After DMD Study Data Readout
  2. The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO
  3. Qualcomm and Progressive jump while Wave Life Sciences drops
  4. Why Wave Life Sciences's Valuation Is Falling By 25%
  5. Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design
  6. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
  7. Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference
  8. Wave Life Sciences Plunges on Clinical Trial Data Delay
  9. Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs
  10. Sarepta plans second Duchenne drug application this year
  11. Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference
  12. Should You Be Worried About Insider Transactions At Wave Life Sciences Ltd. (NASDAQ:WVE)?
  13. Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference
  14. Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update
  15. Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence
  16. Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
  17. Why Wave Life Sciences Ltd.’s (NASDAQ:WVE) CEO Pay Matters To You
  18. New life science internship program launches to help boost diversity
  19. Here's Why Wave Life Sciences Is Crashing Today
  20. Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares